PHARMACY POLICY STATEMENT
Indiana Medicaid

DRUG NAME	Vyvgart (efgartigimod alfa-fcab) and Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc)
BENEFIT TYPE	Medical
STATUS	Prior Authorization Required

Vyvgart, approved by the FDA in December 2021, is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. Vyvgart is a first-in-class IgG1 antibody Fc fragment designed to reduce pathogenic IgG autoantibody levels by inhibiting IgG recycling via the neonatal Fc receptor (FcRn) and increasing IgG degradation. In the phase 3 ADAPT trial, Vyvgart intravenously administered met its primary endpoint, demonstrating clinically meaningful improvements in symptom severity compared with placebo and was generally well-tolerated. Vyvgart Hytrulo is a combination of efgartigamod and hyaluronidase for subcutaneous administration.

Myasthenia gravis is an autoimmune disorder affecting the neuromuscular junction. It is characterized by muscle weakness and fatigue. The cause is an antibody-mediated immunologic attack directed at proteins in the postsynaptic membrane of the neuromuscular junction, most commonly the acetylcholine receptor (90%). Autoantibodies attack the AChR, blocking or destroying the receptors and damaging the neuromuscular junction, which impairs neuromuscular transmission and prevents muscles from contracting, as acetylcholine is unable to activate its receptor. Ocular motility, swallowing, speech, mobility, and respiratory function can all be affected.

Pyridostigmine, an acetylcholinesterase inhibitor, is the initial drug of choice prescribed for MG. It eases symptoms by slowing the breakdown of acetylcholine. If control is inadequate, immunosuppressive treatment is added, such 64(w)8(h4(o)-14()s4d)47(m)47(u)-78(d)-14(i)-23(a)56(n)-14(e,)-7( )-7(a)56(n)/14(g)-14( )-7(o)-14(e

Vyvgart-- Weight <120 kg: 10 mg/kg; Weight 120 kg or greater: 1200 mg (3 vials)

7. Alhaidar MK, Abumurad S, Soliven B, Rezania K. Current Treatment of Myasthenia Gravis. *J Clin Med*.